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Comparison of Germline versus Somatic
BAP1 Mutations for Risk of Metastasis in
Uveal Melanoma
K. G. Ewens1, E. Lalonde1, J. Richards-Yutz1, C. L. Shields2 and A. Ganguly1*
Abstract
Background: Germline mutations in BAP1 have been associated with BAP1-Tumor Predisposition Syndrome
(BAP1-TPDS), a predisposition to multiple tumors within a family that includes uveal melanoma (UM), cutaneous
melanoma, malignant mesothelioma and renal cell carcinoma. Alternatively, somatic mutations in BAP1 in UM have
been associated with high risk for metastasis. In this study, we compare the risk of metastasis in UM that carry
germline versus somatic BAP1 mutations and mutation-negative tumors.
Methods: DNA extracted from 142 UM and matched blood samples was sequenced using Sanger or next
generation sequencing to identify BAP1 gene mutations.
Results: Eleven of 142 UM (8%) carried germline BAP1 mutations, 43 (30%) had somatic mutations, and 88 (62%)
were mutation-negative. All BAP1 mutations identified in blood samples were also present in the matched UM.
There were 52 unique mutations in 54 tumors. All were pathogenic or likely pathogenic.
A comparison of tumors carrying somatic vs. germline mutations, or no mutations, showed a higher frequency of
metastasis in tumors carrying somatic mutations: 74% vs. 36%, P=0.03 and 74% vs. 26% P<0.001, respectively.
Tumors with a somatic mutation compared to mutation-negative had an older age of diagnosis of (61.8 vs. 52.2
years, P=0.002), and shorter time to metastasis (16 vs. 26 months, P=0.04). Kaplan-Meier analysis further showed that
tumors with somatic (vs. germline) mutations demonstrated a greater metastatic risk (P=0.03). Cox multivariate
analysis showed in addition to chromosome-3 monosomy and larger tumor diameter, the presence of BAP1
somatic, but not germline mutations, was significantly associated with risk of metastasis(P=0.02).
Personal or family history of BAP1-TPDS was available for 79 of the cases. All eight cases with germline mutations
reported a history of BAP1-TPDS, which was significantly greater than what was observed in cases with somatic
mutations (10 of 23, P=0.009) or mutation-negative cases (11 of 48, P<0.001).
Conclusions: Defining germline vs. somatic nature of BAP1 mutations in UM can inform the individual about both
the risk of metastasis, and the time to metastasis, which are critically important outcomes for the individual. This
information can also change the cascade screening and surveillance of family members.
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Background
The BRCA1-associated protein 1 (BAP1) gene is located
on chromosome 3p21 and encodes a nuclear localized,
ubiquitin carboxy-terminal hydrolase tumor suppressor
protein [1, 2]. BAP1 has been shown to bind to the
BRCA1 protein enhancing BRCA1-mediated tumor sup-
pression, and is involved in various biological processes
including DNA damage response, regulation of the cell
cycle and cell growth [2, 3]. Germline BAP1 mutations
have been associated with hereditary predisposition to
multiple different cancers that include uveal and cutane-
ous melanoma, malignant mesothelioma on exposure to
asbestos, renal cell carcinoma and other cancer types,
such as lung adenocarcinoma and meningioma, that are
collectively referred to as BAP1 Tumor Predisposition
Syndrome (BAP1-TPDS, OMIM #614327) [4, 5]. In vivo
studies in melanocytic cells, have shown that BAP1 is in-
volved in the maintenance of a melanocytic phenotype;
the depletion of BAP1 protein levels result in dedifferen-
tiation of cells and the acquisition of a more primitive,
stem cell like phenotype [6]. It is well established that
the BAP1 region of chromosome 3p is commonly de-
leted in several cancers including melanomas, breast and
lung cancers, among others [1, 7].
Uveal melanoma (UM) is a rare malignant tumor of
the eye with a frequency of 5.1 per million in the United
States [8], and is the cancer most commonly associated
with the BAP1-TPDS [9]. The prognosis for UM is poor
in approximately 50% of cases primarily due to metasta-
sis to the liver within a short time [10, 11]. Factors such
as large tumor size, location and chromosome 3 mono-
somy [12–18], as well as a specific 12-gene expression pat-
tern [19–21] have all been associated with an increased
risk of metastasis. In addition, the presence of inactivating
somatic [22–29] or germline [30] BAP1 mutations often
in conjunction with chromosome 3 monosomy, loss of
BAP1 expression, or lack of immunohistochemical stain-
ing, have all been associated with metastasizing UM.
Germline BAP1 mutations have been identified in
approximately 2-5% of UM unselected for the presence
of any high risk of hereditary cancers [30–33]. These
studies reported that metastasis occurred more fre-
quently in UM carrying germline mutations in the blood
compared to BAP1 mutation-negative controls, but the
differences were significant only in one study [30],
possibly due to the small number of tumors with germ-
line mutations. In studies where DNA from both tumor
tissue and blood was sequenced to rule out the presence
of germline mutations, the frequency of somatic
BAP1 mutations was considerably higher than that
observed in tumors with germline mutations, ap-
proaching 50% [23, 27, 34]. In other studies where
somatic mutations were detected by BAP1 expression
assays and/or negative immunohistochemical staining
methods, as well as sequencing, the lack of BAP1
expression was also significantly associated with the
risk of metastasis [22–29]. While these studies show a
strong association between somatic BAP1 mutations and
metastasis, the effect of germline changes remains
unclear.
Most studies of BAP1 mutation status in UM have
been carried out using enucleated UM which may not
be representative of how UM are currently treated,
especially smaller tumors that are treated with globe
sparing procedures. In this study of BAP1 mutations in
UM, the presence of germline or somatic mutations was
determined using sequence analysis of DNA extracted
from biopsies of both enucleated globes and fine needle
aspirations (FNA) and from matched blood samples.
Demographic and clinical characteristics of the tumors
and the frequency of metastasis were compared among
tumors with germline or somatic BAP1 mutations and
mutation-negative UM.
Methods
UM cases
A total of 142 UM cases managed by the Ocular
Oncology Service at Wills Eye Hospital, Thomas
Jefferson University, Philadelphia, PA, USA between
1998 and 2016 were evaluated in this study of somatic
and germline BAP1 mutations. Twenty-three tumor
samples were obtained by solid open biopsy of enucle-
ated UM and 119 by fine needle aspirate (FNA) biopsies.
Matched peripheral blood samples were obtained from
all 142 individuals. Data on demographic and clinical
characteristics, metastatic status, location of metastasis
and relevant follow-up times were obtained by retro-
spective chart reviews. Written informed consent was
obtained for all individuals at the time of chromosome
testing of the tumor DNA. This research was approved
by the Institutional Review Board of the University of
Pennsylvania, and is in accordance with the Declaration
of Helsinki.
The 142 UM were initially collected from two cohorts.
Cohort 1 cases (N=90) were chosen from a series of
tumors diagnosed between 1998 and 2013 based on
availability of matched tumor and blood samples. Cohort
2 consisted of 52 cases diagnosed between 2008 and
2016 for which BAP1 testing was requested, typically
due to a personal and/or family history of cancer. The
decision to combine the two sets of tumors into a single
cohort for analysis was based on the finding that cohort
membership was not a significant variable in either uni-
variate (P=0.53) or multivariate (P=0.65) Cox regression
analysis (Table 1). In addition, there was no significant
difference between the two cohorts in the relative
number of tumors carrying germline or somatic BAP1
mutations and mutation-negative tumors (P= 0.76), or in
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the number of cases with personal or family history of
BAP1-TPDS cancers (P=0.35, see below and Additional
file 1: Table S1). There was a significant difference in the
time to metastasis (P=0.01) and in the number of
metastases (P=0.003) between the two cohorts, possibly
due to a longer follow-up time for the cohort 1 tumors
(median=85 months, range 6-191) compared to 24
months (range 4-77 months, P<0.001, Additional file 1:
Table 1 Demographic and tumor characteristics for 142 UM and assessment of their association with metastasis evaluated by Cox
univariate regression for each of the nine variables alone, and multivariate regression that included all variables described in the table
Variables All tumors
N=142 (frequency)
Univariate regression Multivariate regression
P-value Hazard ratio 95% confidence
intervals
P-value Hazard ratio 95% confidence
intervals
Cohort
1 90 (0.63) reference reference
2 52 (0.37) 0.53 0.82 0.44-1.53 0.65 1.18 0.57-2.48
Source of biopsied samplea
FNA, N=119 (0.84) reference reference
BAP1 mutation negative 73 (0.61)
BAP1 mutation positive 46 (0.39)
Enucleated tumor, N= 23 (0.16) 0.01 2.12 1.19-3.76 0.08 2.04 0.92-4.52
BAP1 mutation negative 15 (0.65)
BAP1 mutation positive 8 (0.35)
Age (years) 0.04 1.02 1.00-1.04 0.03 1.02 1.00-1.05
Median 56.7
Mean±SD 55.4±14.7
Range 14-88
Sex
Male 77 (0.54) reference reference
Female 65 (0.46) 0.24 0.73 0.43-1.24 0.73 0.90 0.50-1.63
Chromosome 3
Disomy 63 (0.44) reference reference
Monosomy, partial monosomy
(N=2), mosaic (N=5)
79 (0.56) <0.001 4.64 2.46-8.78 0.008 2.99 1.33-6.72
Tumor diameter (mm) <0.001 1.25 1.17-1.35 <0.001 1.20 1.10-1.31
Median 12.0
Mean±SD 12.5±4.1
Range 5.0-22.0
Tumor thickness (mm) <0.001 1.22 1.13-1.31 0.61 0.97 0.87-1.09
Median 5.7
Mean±SD 6.2±3.3,
Range 1.0-16.5
Ciliary body involvement
Absent 110 (0.78) <0.001 reference reference
Present 32 (0.22) 3.05 1.79-5.20 0.15 1.54 0.85-2.80
BAP1
Negative 88 (0.62) reference reference
Somatic 43 (0.30) <0.001 4.81 2.79-8.28 0.02 2.20 1.13-4.30
Germline 11 (0.08) 0.33 1.70 0.59-4.91 0.81 0.87 0.28-2.72
aThere was no significant difference in the number of BAP1 mutation negative tumors and those carrying germline or somatic mutations UM biopsies from FNA
samples compared to enucleated tumors (P=0.79, Fisher Exact test)
Figures is bold indicate significant P-values <0.05
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Table S1) for cohort 2. However, taking both metastasis
and follow-up time into account in a Kaplan-Meier ana-
lysis, there was no significant association between cohort
membership and metastasis (P=0.52, Additional file 1:
Figure S1).
A personal or family history of BAP1-TPDS syndrome,
defined following the guidelines found in OMIM
#614327 [4] and Pilarski et al [5], was available for a sub-
set of the UM cases. Individuals having at least two
BAP1-TPDS tumors (UM, cutaneous melanoma, malig-
nant mesothelioma, or renal cell carcinoma) themselves,
or one in the UM case plus at least one in a first or
second degree relative were considered as indicative of
BAP1-TPDS syndrome. Cases with non-specific cancer
diagnoses were not included as BAP1-TPDS syndromic
tumors,
BAP1 mutation screening and chromosome 3 copy
number analysis
Genomic DNA was extracted from peripheral blood
lymphocytes using the Gentra Puregene Blood Kit (Cat
No.158489, Qiagen) following the manufacturer’s proto-
col, and from tumor samples as described previously
[15, 35]. Sanger sequencing of DNA from matched
peripheral blood lymphocytes was used to determine the
presence of a germline mutation as noted by
Abdel-Rahman et al [36]. DNA from enucleated tumor
or FNA biopsies was sequenced to identify BAP1 mu-
tations using either Sanger or next generation sequen-
cing of all coding exons and adjacent intronic regions
[37, 38]. Sequence alignment and variant calling was
performed as described previously [37]. The 2015
ACMG guidelines were followed in determining the
degree pathogenicity of all sequence variants [39].
Chromosome 3 copy number was determined by
microsatellite analysis (N=51) or whole genome SNP
array (Affymetrix Human 100K, SNP-5.0 or SNP-6.0 and
Cytoscan HD genotyping arrays, Affymetrix, Santa Clara
CA) [15, 35]. Tumors were categorized as either
disomy-3 (N=63) or monosomy (N=79) that included 72
tumors with complete monosomy-3, two with partial
monosomy and five with a mosaic monosomy 3 indicat-
ing tumor heterogeneity of cells with chromosome-3
disomy and monosomy.
Statistical analyses
Continuous variables (age, tumor diameter and thickness)
were compared using a Mann-Whitney U-test, and
discrete variables (source of tumor sample, cohort 1 or 2,
metastasis status, sex, tumor location and chromosome 3
copy number) using Fisher Exact or chi-square tests
(vassarstats.net). Cox univariate and multivariate propor-
tional hazard regression was used to determine the associ-
ation of clinical and tumor characteristics with metastasis.
The Kaplan-Meier method was used to generate
metastasis-free survival curves that were compared using
a log-rank test. SPSS 24 (IBM, New York, NY) was used
for survival analysis procedures. All tests were two-tailed
and P-values less than 0.05 were considered statistically
significant.
Results
UM individuals and tumor characteristics
Of the 142 UM characterized in this study, 54 (38%)
carried a BAP1 gene mutation. Eleven (8%) of the
mutations were germline and 43 (30%) were somatic.
The remaining 88 (62%) were BAP1 mutation-negative.
The eleven germline mutations were all retained in the
matched UM samples. Thus, there were no cases where
a germline mutation was lost in tumors, with or without
monosomy-3.
Demographic and tumor characteristics for the 142
UM cases are shown in Table 1. The median age of all
individuals was 56.7 years (range=14-88), and 77 (54%)
were males. Overall, 63 (44%) of the tumors carried two
copies of chromosome 3 (disomy), and 79 (56%) carried
one copy of chromosome 3 (monosomy), partial
monosomy or mosaic. The median tumor diameter and
thickness was 12 mm (range=5.0-22.0) and 5.7 mm
(range 1.0-16.5), respectively. The majority of the tumors
had no ciliary body involvement (N=110, 78%). Most tu-
mors were located only in the choroid (N=109, 77%), 26
(18%) were in the choroid plus ciliary body, three (2%)
in the ciliary body, one (1%) in the iris, two (2%) in the
iris plus ciliary body, and one (1%) in the iris plus ciliary
body and choroid. Fifty-nine tumors (42%) metastasized
within a median time of 19 months (range=0-107) while
83 (58%) did not metastasize during the observed
follow-up period (median=56 months, range=4-191
months, Table 2). Thirty-six of 54 tumors with BAP1
mutations metastasized (67%) compared to only 23 of 88
(26%) mutation-negative tumors (P<0.001) within 2-107
months.
BAP1 status was determined for 119 (84%) FNA
biopsies and 23 enucleated tumors (Table 1). There was
a significant difference in the number of metastases
depending on the source of the biopsied sample: 43 of
119 (36%) tumors biopsied from FNA metastasized
compared to 16 of 23 from enucleated globes (70%,
P=0.006). The source of the biopsied sample was also
significantly associated with metastasis in a Cox univari-
ate (P=0.01), but not in a multivariate analysis (0.08,
Table 1). This is not surprising, however, given that
some of the classic prognostic factors for UM metastasis,
larger tumor diameter and thickness and tumor location
which warrant enucleation, were significantly different
between tumors sampled from FNAs or enucleated
tumor samples (P=0.002, >0.001 and 0.02, respectively
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Table 2 Description of demographic and tumor variables with pairwise comparisons for 11 tumors with germline BAP1 mutations,
43 with BAP1 somatic mutations and 88 with no BAP1 mutations
Variables BAP1 germline BAP1 somatic BAP1 negative Pairwise comparisons (P-value)
N=11 (0.08)
(frequency)
N=43 (0.30)
(frequency)
N=88 (0.62)
(frequency)
Germline/
Somatic
Germline/
Negative
Somatic/
Negative
Metastases
Yes N=59 (0.42) 4 (0.36) 32 (0.74) 23 (0.26) 0.03a 0.72a <0.001a
No N=83 (0.58) 7 (0.64) 11 (0.26) 65 (0.74)
Time to metastasis (months) (N=59) N=4 (0.07) N=32 (0.54) N=23 (0.38) 0.07b 0.50b 0.04c
Median (19.0 months) 37.5 16.0 26.0
Mean±SD (26.4±20.9) 35.0±15.8 23±22.5 29.7±19.2
Range (0-107) 16-49 2-45,90,107d 0-84
Follow-up time (months) in tumors
with no metastasis (N=83)
N=7 (0.08) N=11 (0.13) N=65 (0.78) 0.59c 0.25c 0.33c
Median (56.0 months) 24 54.0 58.0
Mean±SD (59.8±39.0) 43.7±39.3 49.9±30.0 63.2±40.1
Range (4-191) 4-109 8-90 5-191
Cohort
1 6 (0.54) 27 (0.63) 57 (0.65) 0.73a 0.74a 0.85a
2 5 (0.46) 16 (0.37) 31 (0.35)
Source of biopsied sample
FNA 10 (0.91) 36 (0.84) 73 (0.83) 0.68a 0.69a 1.00a
Enucleated tumor 1 (0.09) 7 (0.16) 15 (0.17)
BAP1-TPDS personal or family history (N=79 reports)e
Yes, syndromic tumors present
(N=29, 0.37)
8 (1.00) 10 (0.44) 11 (0.23) 0.009a <0.001a 0.10
No syndromic tumors (N=50, 0.63) 0 13 (0.56) 37 (0.77)
Age (years)
Median 59.0 61.8 52.2 0.07c 0.86c 0.002c
Mean±SD 51.9±13.6 61.2±12.8 53.1±15.0,
Range 22-67 28-88 14-84
Sex
Male 7 (0.64) 25 (0.58) 45 (0.51) 1.00a 0.53a 0.46a
Female 4 (0.36) 18 (0.42) 43 (0.49)
Chromosome 3
Disomy 1 (0.09) 3 (0.07) 59 (0.67) 1.0a <0.001a <0.001a
Monosomy, partial monosomy (N=2),
mosaic (N=5)
10 (0.91) 40 (0.93) 26 (0.33)
Tumor diameter (mm)
Median 14.0 14.0 11.5 0.70c 0.23c 0.003c
Mean±SD 13.4±4.4 13.9±3.9 11.7±4.0,
Range 8.0-20.0 6.0-21.5 5.0-22.0
Tumor thickness (mm)
Median 6.6 7.0 5.0 0.41c 0.51c 0.002c
Mean±SD 6.5±3.6 7.5±3.5 5.6±2.9,
Range 1.5-12.3 2.0-16.5 1.0-13.1
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(data not shown). Importantly, there was no difference
in the number of tumors carrying a germline or somatic
mutation or mutation-negative tumors in enucleated tu-
mors compared to FNA samples (P=0.79, Table 1
footnotea).
In a Cox univariate analysis, the presence of a som-
atic, but not a germline BAP1 mutation (hazard ratio
(HR) =4.81, P<0.0001; HR=1.7, P=0.33, respectively,
Table 1) was significantly associated with metastasis.
Other tumor variables that were significant in the
univariate regression analysis included tumor source
(FNA or enucleated tumor, HR= 2.12; P=0.01), age
HR=1.02, P=0.04), chromosome 3 monosomy, larger
tumor diameter and thickness, and ciliary body in-
volvement (HR=4.64, 1.25 and 1.22, respectively; all
P≤0.001). Considering all variables in a multivariate
analysis, the presence of a somatic BAP1 mutation
(HR=2.20, P=0.02), age (HR=1.02, P=0.03) tumor
diameter (HR=1.20, P<0.001), and chromosome 3
monosomy (HR=2.99, P=0.008) remained significant,
while the presence of a germline mutation was not
significant (HR=0.87, P=0.81).
BAP1 Gene Mutations
Fifty-two unique BAP1 mutations were identified in 54 tu-
mors: 43 tumors (30%) carried somatic mutations, while
11 tumors (8%) carried germline mutations (Table 3). All
mutations were defined as pathogenic or likely pathogenic.
These included seven (13%) missense and 15 (28%)
splice-site mutations, three (6%) in-frame deletions and 29
mutations causing premature truncation, including one
large deletion encompassing exons 15-17 and the inter-
vening introns. There was no significant difference in the
frequencies of these categories of mutations found in UM
with germline compared to somatic mutations (P=1.0),
nor in tumors that metastasized compared to those that
did not (P=0.53). Thirty-six (67%) of the mutations were
in the catalytic UCH domain. One splice-site mutation,
c.438-1A>G was present as a germline mutation in one
tumor (UM-23) and as a somatic mutation in two tumors
(UM-11 and UM-27). Thirty-three of these mutations were
previously described in UM by Ewens et al [37] and 13 have
been identified in UM by others (as noted in Table 3).
Although the number of germline mutations was small
(N=11), the locations of these were spread throughout the
gene, similar to the distribution of somatic mutations
(Table 3). Therefore, no new information was inferred
from the location, or the associated functional domains,
that would make the germline mutations have unique
characteristic compared to somatic mutations.
Characterizations of UM with and without BAP1 mutations
Clinical and tumor characteristics of UM carrying BAP1
germline or somatic mutations and mutation-negative
tumors, as well as pairwise comparisons of the three
groups are presented in Table 2. There was no signifi-
cant difference in the cohort, source of biopsy sample,
or sex of the individuals among the three categories of
mutations. The age at diagnosis of individuals with som-
atic mutations was significantly older (61.8 years,
range=28-88) than individuals with mutation-negative
tumors (median=52.2 years, range=14-84 years, P=0.002)
and approached significance compared to individuals with
a tumor carrying a germline mutation (median=59.0 years,
range=22-67, P=0.07).
There was a significant difference in the comparison
of chromosome 3 monosomy in mutation-negative tu-
mors compared to tumors with either germline or som-
atic mutations. Only 26 (33%) mutation-negative tumors
carried monosomy 3, while ten (91%) tumors with germ-
line mutations and 40 (93%) with somatic mutations
were chromosome 3 monosomy (P<0.001 in both cases).
A comparison of chromosome 3 copy number between
tumors with germline vs. somatic mutations (91% vs.
93%) was not significant (P=1.0, Table 2). There were
four tumors with BAP1 mutations and chromosome 3
disomy (marked with superscript b in Table 3). These
would suggest that chromosome 3 loss was not a
Table 2 Description of demographic and tumor variables with pairwise comparisons for 11 tumors with germline BAP1 mutations,
43 with BAP1 somatic mutations and 88 with no BAP1 mutations (Continued)
Variables BAP1 germline BAP1 somatic BAP1 negative Pairwise comparisons (P-value)
N=11 (0.08)
(frequency)
N=43 (0.30)
(frequency)
N=88 (0.62)
(frequency)
Germline/
Somatic
Germline/
Negative
Somatic/
Negative
Ciliary body involvement
Absent 8 (0.73) 28 (0.65) 74 (0.84) 0.73a 0.40a 0.02a
Present 3 (0.27) 15 (0.35) 14 (0.14)
aAssociation test performed using two-tailed Fisher Exact or Chi-square tests
bReported P-values are calculated from a normal approximation of the Mann Whitney test statistic
cTests of means of quantitative variables performed using Mann-Whitney U tests
dThe time for metastasis for 30 of the tumors with somatic mutations was 2-45 months. The time to metastasis for the remaining two tumors was 90 and
107 months
eBAP1-TPDS, BAP1-tumor predisposition syndrome as defined in OMIM #614327 [4] and Pilarski et al [5]
Figures is bold indicate significant P-values <0.05
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necessary consequence of BAP1 loss. The one germline
mutation was a splice-site mutation, intron 3, c.122
+1G>C. The three somatic mutations included one
splice-site mutation (intron 6, c.438-2A>G) and two
truncating mutations: exon 4, c.178C>T (p.Arg60X) and
a large deletion of exons 15-17 and the intervening
introns. The tumor carrying the exon 4, c.178C>T
(p.Arg60X) truncating mutation metastasized at 11
months, but the other three tumors had not metasta-
sized within 24 months (c.122+1G>C) or within at least
65 months (c.438-2A>G and the large three exon
deletion).
Tumors with BAP1 somatic mutations had a signifi-
cantly larger median diameter (14.0 mm, range=6.0-21.5)
and thickness (7.0 mm, range=2.0-16.5) compared to
mutation negative tumors (median diameter=11.5 mm,
range=5.0-22.0; thickness=5.0 mm, range=0.0-13.1,
P=0.003 and P=0.002 respectively, Table 2). However,
there was no significant difference in the tumor diameter
or thickness between BAP1 germline tumors and tumors
with either somatic mutations (P=0.70 and P=0.41, re-
spectively), or BAP1-negative tumors (P=0.23 and
P=0.51, respectively). Table 2 shows that there was also a
significant difference in ciliary body involvement of
tumors carrying a somatic mutation, where the tumor
was more likely to have ciliary body involvement (33%)
compared to BAP1-negative tumors (14%, P=0.04), but
not compared with those with a germline mutation
(27%, P=1.0).
Tumors carrying BAP1 somatic mutations metastasized
significantly more often (32 of 43, 74%) compared to those
with either BAP1 germline mutations (4 of 11, 36%,
P=0.03) or to BAP1 mutation-negative tumors (23 of 88,
26%, P<0.001, Table 2). However, there was no significant
difference in the frequency of metastasis between tumors
with germline mutations and BAP1-negative tumors
(P=0.72). This finding was corroborated by the multivari-
ate regression analyses shown in Table 1 indicating that
somatic, but not germline BAP1 mutations, were signifi-
cantly associated with metastasis (P=0.03 and 0.70, re-
spectively). Kaplan-Meier analysis (Figure 1) also showed
that tumors with a BAP1 somatic mutation had a signifi-
cantly poorer metastatic outcome compared to those with
germline mutations (P=0.03) or mutation-negative tumors
(P<0.001), but the difference between tumors with germ-
line mutations and BAP1 mutation-negative tumors was
not significant (P=0.23). The time to metastasis was also
significantly shorter in the tumors with somatic mutations
(median=16.0 months, range=2-107) compared to BAP1--
negative tumors (median=26 months, range=0-84 months,
P=0.04, Table 2).
A positive personal and/or family history of BAP1-
TPDS tumors was reported for 29 (37%) of the 79 cases
that provided information of other cancers in themselves
or their families (Table 2). There were eight cases that
carried a germline mutation with information on
personal or familial cancers; all had a positive history of
BAP1-TPDS. Comparisons of BAP1-TPDS tumors in
UM cases with a germline (8, 100%) vs. somatic
mutation (10, 44%) or germline vs. mutation-negative
(11, 23%) were significant (P=0.009 and P<0.001, re-
spectively), while a comparison of those with somatic
mutations was not significantly different from those with
mutation-negative tumors (P=0.10)
Discussion
Inactivating somatic mutations in the BAP1 gene in UM
were first identified and associated with metastatic
disease in 2010 [23]. Subsequent to this original publi-
cation, there have been numerous studies characteriz-
ing BAP1 somatic [22, 24–29, 40–43] and germline
[9, 30, 32, 33] mutations in UM. However, to our
knowledge, this is the first report directly comparing
risk of metastasis in tumors carrying germline or
somatic BAP1 mutations and mutation-negative tu-
mors. In this study, the presence of somatic muta-
tions was strictly defined as those found in tumors,
and not in matched blood samples. A second import-
ant difference in this study is that, compared to most
other reports where UM tumors analyzed for BAP1
mutations were comprised primarily of samples
biopsied from larger, enucleated tumors, 84% of the
samples analyzed in this study were from FNA biop-
sies. We found no significant difference in the fre-
quency of somatic and germline mutations in biopsies
from FNAs compared to enucleated tumors. Since the
P=0.03
BAP1 negative, N=88
BAP1 germline, N=11
BAP1 somatic, N=43
P=0.20
P<0.001
P<0.001
Fig. 1 Kaplan-Meier curves showing metastasis-free survival following
diagnosis for 142 UM stratified by BAP1 mutation status
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majority of UM are currently being treated by globe
sparing procedures, it was important to determine
whether the consequences of carrying a BAP1 muta-
tion identified in larger enucleated tumors could be
applied to smaller UM biopsied by FNA sampling.
It is well established that tumor characteristics such as
tumor diameter, ciliary body involvement and chromo-
some 3 monosomy are all associated with poor progno-
sis as measured by the development of metastases
within 48 months after the primary is treated [12–18]. It
has also been shown that that these same variables are sig-
nificantly associated with BAP1 mutation status in tumors
with somatic or germline mutations [24, 25, 28, 30]. In
this study, multivariate regression analysis showed that in
addition to these classic tumor variables, the presence of
somatic, but not germline, BAP1 mutations was signifi-
cantly associated with metastasis (HR=2.20, P=0.02;
HR=0.87, P=0.81, respectively). Kaplan-Meier analysis fur-
ther showed that tumors with somatic mutations were as-
sociated with the poorest metastatic outcome, while there
was no significant difference between tumors carrying a
germline mutation and mutation-negative tumors.
Furthermore, the time to metastasis was seven months
shorter for individuals whose tumors carried somatic mu-
tations compared to mutation-negative tumors (P=0.04)
suggesting a more aggressive phenotype. Thus, in a
previous publication [37] we showed that tumors with any
mutation in the BAP1 gene, in combination with chromo-
some 3-monosomy, have the highest risk of metastasis
(HR=11.5). In this manuscript we show that monosomy 3
plus a somatic mutation in the BAP1 gene, as opposed to
a germline mutation, have a significantly higher risk of
metastasis (P=0.01, H.R.=2.81) and a shorter time to me-
tastasis compared to the ones with a germline mutation.
Given that somatic BAP1 mutations appear to have a
highly significant association with poor metastatic prog-
nosis, it is surprising that the age of diagnosis of the in-
dividuals whose tumors carried somatic mutations was
significantly older (median=61.8 years) compared to
those with mutation-negative tumors (median=52.2
years, P=0.002). Previous studies have also reported that
tumors with somatic mutations were diagnosed at least 8
years later than mutation-negative controls [24, 27, 29],
but the significance of this observation is not clear.
Among the 54 tumors with BAP1 mutations, there
were four with chromosome 3 disomy. It cannot be
ruled out that although these tumors appeared to be
disomy-3, small deletions not detectable on the SNP
arrays leading to partial monosomy or heterogeneity of
the tumor sample could be responsible for this finding.
Alternatively, in some cases it is possible the during
tumor evolution, BAP1 mutation on one copy of
chromosome 3 could precede the loss of the other copy
of chromosome 3. While several studies have found total
concordance between the presence BAP1 mutations and
monosomy 3 [23, 27, 40], others using sequencing, gene
expression, and/or immunostaining methods have iden-
tified BAP1 mutations in a small number of tumors with
disomy 3 [24, 25, 28, 44].
One interesting observation in this study was the pres-
ence of BAP1-TPDS history in 44% of somatic cases and
23% of mutation negative tumors. The data on
BAP1-TPDS was based on self-reported personal and
family history of cancer. We classified individuals as
having BAP1-TPDS if they carried at least two relevant
tumors in their personal or family history. Since it is
self-reported, the information can be imprecise, and
there is a possibility for over/under representation of the
BAP1-TPDS cases as well.
While the presence of germline BAP1 mutations in
cancers associated with BAP1-TPSD is well documented,
the role of somatic mutations in this syndrome is not
well studied. It is possible that the presence of TPDS in
our cohort of UM cases that have a somatic BAP1
mutation or are mutation-negative could be interpreted
as evidence for the existence of a second type of the
syndrome associated with mutations in a second gene
different from BAP1.
A major strength of this study is that it includes UM
sampled from enucleated tumors and FNAs with both
somatic and germline BAP1 mutations. However, it is
limited by the small number of tumors with germline
mutations. It is important to confirm these findings in a
larger cohort of UM.
Conclusions
This study identified significant differences in the risk of
metastasis for individuals whose tumors carry somatic
vs. germline BAP1 mutations. While overall 36 of 59
(61%) metastasizing tumors carried a BAP1 mutation,
only 7% carried germline mutations, compared to 54%
with somatic mutations. From the viewpoint of counsel-
ing individuals with UM, there are different implications
depending on whether the mutation is classified as
germline or somatic. The most relevant information for
the individuals with UM is the risk of metastasis, as well
as an estimate of metastasis-free survival. The presence
of germline mutations can provide the individual with
information concerning the risk of development of other
cancers themselves or in other family members, while
information about the presence of somatic mutations is
relevant to their individual risk of developing metastases
within a shorter time period. Thus it is important to
determine whether a tumor carries a BAP1 mutation,
and if positive, to also evaluate a matched blood sample to
establish whether the mutation is germline or somatic. In
addition, this information can also change the cascade
screening and surveillance of the family members.
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